Laboratory Medicine ›› 2019, Vol. 34 ›› Issue (12): 1059-1065.DOI: 10.3969/j.issn.1673-8640.2019.12.001
WANG Yanmin, TIAN Guoli, JI Wei
Received:
2018-12-20
Online:
2019-12-30
Published:
2020-01-03
CLC Number:
WANG Yanmin, TIAN Guoli, JI Wei. Role of tandem mass spectrometry for screening X-linked adrenoleukodystrophy[J]. Laboratory Medicine, 2019, 34(12): 1059-1065.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2019.12.001
项目 | 母离子>子离子(m/z) | 锥孔电压(V) | 碰撞能量(V) |
---|---|---|---|
C20 | 456.4>85.0 | 75 | 35 |
C22 | 484.4>85.0 | 75 | 35 |
C24 | 512.5>85.0 | 75 | 35 |
C26 | 540.5>85.0 | 75 | 35 |
2H3-C26 | 543.5>85.0 | 75 | 35 |
C20:0-LPC | 552.4>104.1 | 75 | 33 |
C22:0-LPC | 580.4>104.1 | 75 | 33 |
C24:0-LPC | 608.5>104.1 | 75 | 33 |
C26:0-LPC | 636.5>104.1 | 75 | 33 |
2H4-C26:0-LPC | 640.5>104.1 | 75 | 33 |
项目 | 母离子>子离子(m/z) | 锥孔电压(V) | 碰撞能量(V) |
---|---|---|---|
C20 | 456.4>85.0 | 75 | 35 |
C22 | 484.4>85.0 | 75 | 35 |
C24 | 512.5>85.0 | 75 | 35 |
C26 | 540.5>85.0 | 75 | 35 |
2H3-C26 | 543.5>85.0 | 75 | 35 |
C20:0-LPC | 552.4>104.1 | 75 | 33 |
C22:0-LPC | 580.4>104.1 | 75 | 33 |
C24:0-LPC | 608.5>104.1 | 75 | 33 |
C26:0-LPC | 636.5>104.1 | 75 | 33 |
2H4-C26:0-LPC | 640.5>104.1 | 75 | 33 |
项目 | 参考值(μmol/L) | 准确度 | 精密度(CV) | 线性方程 | r2值 | |||
---|---|---|---|---|---|---|---|---|
批内(%) | 批间(%) | 批内(%) | 批间(%) | |||||
C26 | Y=2.24X-0.03 | 0.996 | ||||||
低水平 | 0.73 | 96.23 | 93.25 | 4.16 | 8.29 | |||
高水平 | 1.77 | 104.94 | 102.38 | 5.57 | 7.45 | |||
C26:0-LPC | Y=3.02X+0.15 | 0.994 | ||||||
低水平 | 0.95 | 96.58 | 95.71 | 7.75 | 9.17 | |||
高水平 | 3.26 | 98.82 | 101.22 | 8.68 | 8.11 |
项目 | 参考值(μmol/L) | 准确度 | 精密度(CV) | 线性方程 | r2值 | |||
---|---|---|---|---|---|---|---|---|
批内(%) | 批间(%) | 批内(%) | 批间(%) | |||||
C26 | Y=2.24X-0.03 | 0.996 | ||||||
低水平 | 0.73 | 96.23 | 93.25 | 4.16 | 8.29 | |||
高水平 | 1.77 | 104.94 | 102.38 | 5.57 | 7.45 | |||
C26:0-LPC | Y=3.02X+0.15 | 0.994 | ||||||
低水平 | 0.95 | 96.58 | 95.71 | 7.75 | 9.17 | |||
高水平 | 3.26 | 98.82 | 101.22 | 8.68 | 8.11 |
组别 | 例数 | C20(μmol/L) | C22(μmol/L) | C24(μmol/L) | C26(μmol/L) | |
---|---|---|---|---|---|---|
X-ALD组 | 10 | 0.02(0.01~0.02) | 0.01(0.01~0.01) | 0.10(0.07~0.12) | 0.12(0.09~0.15) | |
正常对照组 | 3 550 | 0.01(0.01~0.02) | 0.01(0.00~0.01) | 0.02(0.02~0.03) | 0.01(0.009-0.010) | |
U值 | 2.401 5 | 2.892 9 | 5.783 8 | 8.697 4 | ||
P值 | 0.016 1 | 0.003 8 | <0.000 1 | <0.000 1 | ||
组别 | C20:0-LPC(μmol/L) | C22:0-LPC(μmol/L) | C24:0-LPC(μmol/L) | C26:0-LPC(μmol/L) | ||
X-ALD组 | 0.32(0.27~0.57) | 0.245(0.19~0.31) | 0.72(0.59~0.93) | 0.68(0.41~0.88) | ||
正常对照组 | 0.18(0.14~0.23) | 0.14(0.12~0.18) | 0.38(0.32~0.45) | 0.20(0.17~0.24) | ||
U值 | 3.849 6 | 3.680 9 | 4.696 3 | 5.168 4 | ||
P值 | 0.000 1 | 0.000 2 | <0.000 1 | <0.000 1 | ||
组别 | C24/C20比值 | C24/C22比值 | C26/C20比值 | C26/C22比值 | ||
X-ALD组 | 5.25(4.54~7.75) | 8.50(7.45~10.01) | 7.08(6.578~8.63) | 10.00(9.03~12.11) | ||
正常对照组 | 2.00(1.02~2.09) | 2.00(1.78~3.01) | 1.00(0.50~1.03) | 1.00(0.91~1.16) | ||
U值 | 5.610 4 | 5.801 7 | 6.391 4 | 7.966 7 | ||
P值 | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 | ||
组别 | C24:0-LPC/C20:0-LPC比值 | C24:0-LPC/C22:0-LPC比值 | C26:0-LPC/C20:0-LPC比值 | C26:0-LPC/C22:0-LPC比值 | ||
X-ALD组 | 2.12(1.49~2.67) | 3.13(2.32~3.98) | 1.50(0.96~2.56) | 2.50(1.79~3.55) | ||
正常对照组 | 2.05(1.64~2.57) | 2.64(2.19~3.13) | 1.10(0.85~1.43) | 1.41(1.13~1.73) | ||
U值 | -0.033 4 | 1.432 7 | 1.776 6 | 3.037 6 | ||
P值 | 0.973 2 | 0.151 9 | 0.075 6 | 0.002 4 |
组别 | 例数 | C20(μmol/L) | C22(μmol/L) | C24(μmol/L) | C26(μmol/L) | |
---|---|---|---|---|---|---|
X-ALD组 | 10 | 0.02(0.01~0.02) | 0.01(0.01~0.01) | 0.10(0.07~0.12) | 0.12(0.09~0.15) | |
正常对照组 | 3 550 | 0.01(0.01~0.02) | 0.01(0.00~0.01) | 0.02(0.02~0.03) | 0.01(0.009-0.010) | |
U值 | 2.401 5 | 2.892 9 | 5.783 8 | 8.697 4 | ||
P值 | 0.016 1 | 0.003 8 | <0.000 1 | <0.000 1 | ||
组别 | C20:0-LPC(μmol/L) | C22:0-LPC(μmol/L) | C24:0-LPC(μmol/L) | C26:0-LPC(μmol/L) | ||
X-ALD组 | 0.32(0.27~0.57) | 0.245(0.19~0.31) | 0.72(0.59~0.93) | 0.68(0.41~0.88) | ||
正常对照组 | 0.18(0.14~0.23) | 0.14(0.12~0.18) | 0.38(0.32~0.45) | 0.20(0.17~0.24) | ||
U值 | 3.849 6 | 3.680 9 | 4.696 3 | 5.168 4 | ||
P值 | 0.000 1 | 0.000 2 | <0.000 1 | <0.000 1 | ||
组别 | C24/C20比值 | C24/C22比值 | C26/C20比值 | C26/C22比值 | ||
X-ALD组 | 5.25(4.54~7.75) | 8.50(7.45~10.01) | 7.08(6.578~8.63) | 10.00(9.03~12.11) | ||
正常对照组 | 2.00(1.02~2.09) | 2.00(1.78~3.01) | 1.00(0.50~1.03) | 1.00(0.91~1.16) | ||
U值 | 5.610 4 | 5.801 7 | 6.391 4 | 7.966 7 | ||
P值 | <0.000 1 | <0.000 1 | <0.000 1 | <0.000 1 | ||
组别 | C24:0-LPC/C20:0-LPC比值 | C24:0-LPC/C22:0-LPC比值 | C26:0-LPC/C20:0-LPC比值 | C26:0-LPC/C22:0-LPC比值 | ||
X-ALD组 | 2.12(1.49~2.67) | 3.13(2.32~3.98) | 1.50(0.96~2.56) | 2.50(1.79~3.55) | ||
正常对照组 | 2.05(1.64~2.57) | 2.64(2.19~3.13) | 1.10(0.85~1.43) | 1.41(1.13~1.73) | ||
U值 | -0.033 4 | 1.432 7 | 1.776 6 | 3.037 6 | ||
P值 | 0.973 2 | 0.151 9 | 0.075 6 | 0.002 4 |
变量 | 项目 | 偏回归系数 |
---|---|---|
截距 | -0.103 8 | |
X1 | C22 | 0.072 3 |
X2 | C24 | 0.026 5 |
X3 | C26 | 0.175 3 |
X4 | C20:0-LPC | 0.043 1 |
X5 | C22:0-LPC | 0.023 4 |
X6 | C24:0-LPC | 0.022 9 |
X7 | C26:0-LPC | 0.079 2 |
X8 | C24/C20比值 | 0.000 7 |
X9 | C24/C22比值 | -0.029 2 |
X10 | C26/C20比值 | -0.006 2 |
X11 | C26/C22比值 | 0.130 0 |
X12 | C26:0-LPC/C22:0-LPC比值 | 0.012 5 |
变量 | 项目 | 偏回归系数 |
---|---|---|
截距 | -0.103 8 | |
X1 | C22 | 0.072 3 |
X2 | C24 | 0.026 5 |
X3 | C26 | 0.175 3 |
X4 | C20:0-LPC | 0.043 1 |
X5 | C22:0-LPC | 0.023 4 |
X6 | C24:0-LPC | 0.022 9 |
X7 | C26:0-LPC | 0.079 2 |
X8 | C24/C20比值 | 0.000 7 |
X9 | C24/C22比值 | -0.029 2 |
X10 | C26/C20比值 | -0.006 2 |
X11 | C26/C22比值 | 0.130 0 |
X12 | C26:0-LPC/C22:0-LPC比值 | 0.012 5 |
[1] | BERGER J,FORSS-PETTER S,EICHLER F S.Pathophysiology of X-linked adrenoleukodystrophy[J]. Biochim,2014,98(100):135-142. |
[2] | KEMPER A R,BROSCO J,COMEAU A M,et al.Newborn screening for X-linked adrenoleukodystrophy:evidence summary and advisory committee recommendation[J]. Genet Med,2017,19(1):121-126. |
[3] | TURGEON C T,MOSER A B,MØRKRID L,et al. Streamlined determination of lysophosphatidylcholines in dried blood spots for newborn screening of X-linked adrenoleukodystrophy[J]. Mol Genet Metab,2015,114(1):46-50. |
[4] | BOEHM C D,CUTTING G R,LACHTERMACHER M B,et al.Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy[J]. Mol Genet Metab,1999,66(2):128-136. |
[5] | WU C,IWAMOTO T,IGARASHI J,et al.Application of a diagnostic methodology by quantification of 26:0 lysophosphatidylcholine in dried blood spots for Japanese newborn screening of X-linked adrenoleukodystrophy[J]. Mol Genet Metab Rep,2017,12:115-118. |
[6] | VAN DE BEEK M C,DIJKSTRA I M,VAN LENTHE H,et al. C26:0-carnitine is a new biomarker for X-linked adrenoleukodystrophy in mice and man[J]. PLoS One,2016,11(4): e0154597. |
[7] | BEZMAN L,MOSER A B,RAYMOND G V,et al.Adrenoleukodystrophy:incidence,new mutation rate,and results of extended family screening[J]. Ann Neurol,2001,49(4):512-517. |
[8] | MOSER H W,MAHMOOD A,RAYMOND G V.X-linked adrenoleukodystrophy[J]. Nat Clin Pract Neurol,2007,3(3):140-151. |
[9] | MAHMOOD A,RAYMOND G V,DUBEY P,et al.Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy:a comparison study[J]. Lancet Neurol,2007,6(8):687-692. |
[10] | RAJABI F.Updates in newborn screening[J]. Pediatr Ann,2018,47(5):e187-e190. |
[11] | VOGEL B H,BRADLEY S E,ADAMS D J,et al.Newborn screening for X-linked adrenoleukodystrophy in New York State:diagnostic protocol,surveillance protocol and treatment guidelines[J]. Mol Genet Metab,2015,114(4):599-603. |
[12] | KEMPER A R,BROSCO J,COMEAU A M,et al.Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation[J]. Genet Med,2017,19(1):121-126. |
[13] | BASSEY A,CHILCOTT J B,LEAVISS J,et al.Economic impact of screening for X-linked adrenoleukodystrophy within a newborn blood spot screening program[J]. Orphanet J Rare Dis,2018,13:179-190. |
[14] | 韩鎏,倪君君,相婷,等. 液相色谱-串联质谱方法检测血清中极长链脂肪酸含量[J]. 中华检验医学杂志,2011,34(1):30-35. |
[15] | 魏虹,应艳琴,梁雁,等. 血浆极长链脂肪酸GC-MS测定方法的建立和应用[J]. 临床儿科杂志,2005,23(8):519-522. |
[16] | MOSER A B,KREITER N,BEZMAN L,et al.Plasma very long chain fatty acids in 3 000 peroxisome disease patients and 29 000 controls[J]. Ann Neurol,1999,45(1):100-110. |
[17] | HUBBARD W C,MOSER A B,TORTORELLI S,et al.Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders:preliminary findings[J]. Mol Genet Metab,2006,89(1-2):185-187. |
[18] | HUFFNAGEL I C,VAN DE BEEK M C,SHOWERS A L,et al. Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy[J]. Mol Genet Metab,2017,122(4):209-215. |
[19] | TURGEON C T,MOSER A B,MØRKRID L,et al. Streamlined determination of lysophosphatidylcholines in dried blood spots for newborn screening of X-linked adrenoleukodystrophy[J]. Mol Genet Metab,2015,114(1):46-50. |
[1] | LI Xijiu, ZHOU Jianwei, ZHANG Qin, LONG Yunlin, WU Yingsong. Establishment and performance evaluation of UPLC-MS/MS for 6 markers in dried blood spots [J]. Laboratory Medicine, 2023, 38(5): 446-453. |
[2] | XU Weixin, CHEN Qing, DU Wenyong, GAO Yan. Plasma metabolic markers in patients with insomnia disorder [J]. Laboratory Medicine, 2023, 38(5): 454-459. |
[3] | WU Jie, LI Zenghe, CHEN Baorong, KONG Xujing. Establishment of traceable steroid hormone standard curve for dried blood spot samples [J]. Laboratory Medicine, 2023, 38(5): 489-493. |
[4] | Expert Group on the Consensus on Androgen Testing in Polycystic Ovary Syndrome China Association for Promotion of Health Science and Technology-Fertility Protection and Preservation Committee. Consensus on androgen testing in polycystic ovary syndrome [J]. Laboratory Medicine, 2023, 38(3): 203-208. |
[5] | YANG Xiaodong, LI Quanle, PAN Qingqing, ZHOU Jing, XIE Yangmin, ZOU Jihua, SHEN Min, ZHANG Man. Establishment and performance evaluation of candidate reference measurement procedure for the determination of immunosuppressive drugs in human whole blood by ID-LC-MS/MS [J]. Laboratory Medicine, 2023, 38(3): 215-222. |
[6] | WANG Yajie, ZU Bailing, GAN Chenxin, WU Jiaoxiang, SHU Jie, HANG Chen, CHEN Minghui, LIN Fujun, HU Zhigang, HUANG Biao, SHENG Huiming. Identification of plasma differential peptids in PLA2R1-related membranous nephropathy patients [J]. Laboratory Medicine, 2023, 38(3): 223-229. |
[7] | TANG Ningbo, LIU Guancai, LIU Xiaoyu, YANG Fengfan, GONG Zhimei, SUN Keqi. Establishment and evaluation for the determination of serum digitoxin as a candidate reference method [J]. Laboratory Medicine, 2022, 37(5): 456-462. |
[8] | XU Runhao, ZOU Chen, CAO Yun, CHEN Feng, LIU Yijing, ZHANG Shulin, ZHANG Jie. Roles of serum amino acid determinations in the diagnosis of early non-small-cell lung cancer [J]. Laboratory Medicine, 2022, 37(12): 1157-1163. |
[9] | LI Bingling, CHENG Yating, ZHAO Beibei, SHE Xuhui, DONG Heng, YU Mujun. Evaluation of surrogate matrices for serum 25-hydroxyvitamin D calibrators by LC-MS/MS [J]. Laboratory Medicine, 2021, 36(2): 213-218. |
[10] | TANG Chengfang, WEI Qingxiu, QIN Jianrong, TANG Fang, LIU Sichi, JIANG Xiang, HUANG Yonglan. Comparison of different-brand tandem mass spectrometers for newborn screening of genetic metabolic diseases [J]. Laboratory Medicine, 2021, 36(10): 1042-1046. |
[11] | SUN Hewei, JU Yi, ZHU Lingfeng, LI Qing, JIN Zhonggan, ZHANG Sujie. Isotope dilution liquid chromatography tandem mass spectrometry candidate reference method for serum testosterone [J]. Laboratory Medicine, 2021, 36(10): 1064-1069. |
[12] | XU Runhao, ZOU Chen, ZHANG Jie, LI Min, ZHANG Shulin. Application of serum bile acid spectrum in the differential diagnosis of pneumonia and lung cancer [J]. Laboratory Medicine, 2021, 36(1): 1-7. |
[13] | ZOU Jihua, LI Quanle, SHEN Min, ZHANG Man, YANG Xiaodong, TU Minmin, FENG Dongfang, SUN Hongna. Establishment and performance evaluation of candidate reference measurement procedure for serum aldosterone by liquid chromatography-tandem mass spectrometry [J]. Laboratory Medicine, 2020, 35(8): 811-817. |
[14] | CAO Zheng, LIU Jingrui, XIE Xin, LIU Yilin, DONG Ying, TANG Guodong, ZHAI Yanhong. Determination of lecithin and sphingomyelin in amniotic fluid by ultra-performance liquid chromatography-tandem mass spectrometry [J]. Laboratory Medicine, 2020, 35(3): 233-237. |
[15] | ZHANG Sujie, JU Yi, LI Qing, SUN Hewei, FENG Xueqing, JIN Zhonggan, LI Shuijun, LI Yujie, LI Jinrong. Analysis of serum 25-hydroxyvitamin D levels in healthy subjects [J]. Laboratory Medicine, 2020, 35(10): 1028-1031. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||